Layout H – onkoview.com

Layout H

Clonal evolution of tumours

Molecular action of p53 in carcinogenesis

Molecular actions of the PML-RARα fusion protein in promyelocytic leukaemia

The cell cycle – Part 1: Phases and checkpoints

The cell cycle – Part 2: Cyclins, cyclin dependent kinases (CDKs), CDK inhibitors

Apoptosis

Oncogenic activation of receptor tyrosine kinases

The EGF receptor tyrosine protein kinases

The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors – Part 1: Inhibition of receptor activation via antibodies

The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors – Part 2: Blocking of EGF receptor signaling via tyrosine kinase inhibitors

BCR-ABL1 and the Philadelphia chromosome – Part 1: Normal and aberrant karyograms

BCR-ABL1 and the Philadelphia chromosome – Part 2: The Philadelphia chromosome

Layout H (with G as starter)

Onkoview 2010

Clonal evolution of tumours

Onkoview 2010

Molecular action of p53 in carcinogenesis

Onkoview 2010

Molecular actions of the PML-RARα fusion protein in promyelocytic leukaemia

Onkoview 2010

The cell cycle – Part 1: Phases and checkpoints

The cell cycle – Part 2: Cyclins, cyclin dependent kinases (CDKs), CDK inhibitors

Apoptosis

Oncogenic activation of receptor tyrosine kinases

The EGF receptor tyrosine protein kinases

The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors – Part 1: Inhibition of receptor activation via antibodies

The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors – Part 2: Blocking of EGF receptor signaling via tyrosine kinase inhibitors

BCR-ABL1 and the Philadelphia chromosome – Part 1: Normal and aberrant karyograms

BCR-ABL1 and the Philadelphia chromosome – Part 2: The Philadelphia chromosome

Layout H (with load more button)

Clonal evolution of tumours

Molecular action of p53 in carcinogenesis

Molecular actions of the PML-RARα fusion protein in promyelocytic leukaemia

The cell cycle – Part 1: Phases and checkpoints

The cell cycle – Part 2: Cyclins, cyclin dependent kinases (CDKs), CDK inhibitors

Apoptosis

Oncogenic activation of receptor tyrosine kinases

The EGF receptor tyrosine protein kinases

The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors – Part 1: Inhibition of receptor activation via antibodies

The EGF receptor tyrosine protein kinases and the therapy of tumors with activated EGF receptors – Part 2: Blocking of EGF receptor signaling via tyrosine kinase inhibitors

BCR-ABL1 and the Philadelphia chromosome – Part 1: Normal and aberrant karyograms

BCR-ABL1 and the Philadelphia chromosome – Part 2: The Philadelphia chromosome